Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 5Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Neurotoxicity Syndromes 1Melanoma 1Gastrointestinal Neoplasms 1Cognitive Dysfunction 1Central Nervous System Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 4Sodium Chloride 3Paclitaxel 3Carboplatin 3xaliproden 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Magnesium Sulfate 2Leucovorin 2Fluorouracil 2Calcium Gluconate 2neurotropin 1glutamic acid diethyl ester 1Vitamin E 1Thioctic Acid 1Temozolomide 1Saline Solution 1Radiosurgery 1Prednisolone 1Methylprednisolone 1Memantine 1Lamotrigine 1Ketamine 1Glutathione 1Glutamic Acid 1Ginkgo Extract 1Gabapentin 1Duloxetine Hydrochloride 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neurotoxicity Syndromes × Memantine × Clear all
NCT00566852 2017-08-21

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Radiation Therapy Oncology Group

Phase 3 Completed
554 enrolled 12 charts
CNS

Brain Neoplasms, Neoplasm Metastasis, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡